GBIO
Generation Bio Co. [GBIO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
GBIO Stock Summary
Top 10 Correlated ETFs
GBIO
Top 10 Correlated Stocks
GBIO
In the News
GBIO Financial details
Company Rating
-
Market Cap
245.97M
Income
-122.51M
Revenue
5.9M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
174
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-1.1
Forward P/E
-
PEG
0.66
P/S
42.69
P/B
0.56
P/C
-
P/FCF
-2.38
Quick Ratio
8.89
Current Ratio
9.07
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.89
EPS next Y
-
EPS next Q
-
EPS this Y
-13.66%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
34.11%
EPS Q/Q
23.26%
-
-
-
-
SMA20
-30.85%
SMA50
-52.9%
SMA100
-75.29%
Inst Own
-
Inst Trans
-
ROA
-31%
ROE
-45%
ROC
-0.39%
Gross Margin
100%
Oper. Margin
-4456%
Profit Margin
-3881%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.86-6.98
52W High
-
52W Low
-
RSI
28.69
Rel Volume
2.05
Avg Volume
251.92K
Volume
517.63K
Perf Week
-3.14%
Perf Month
-41.33%
Perf Quarter
-76.07%
Perf Half Y
-76.44%
-
-
-
-
Beta
2.788
-
-
Volatility
0.03%, 0.12%
Prev Close
-0.78%
Price
0.6102
Change
-11.57%
Company Profile
- Volume Average 251.92K
- Market Capitalization 245.97M
- Employee 174
- CEO Dr. Cameron Geoffrey McDonough M.D.
- Headquarters Cambridge,MA,US
- IPO Date 2020-06-12
-
Website
https://generationbio.com 
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
